Alzprotect announced its lead candidate AZP2006 has been chosen as one of the first two therapies to be tested in a phase 2 clinical trial for progressive supranuclear palsy (PSP). According to the company, the multicenter platform trial will also evaluate AADvac1, a tau-targeting vaccine developed by Axon Neuroscience.
The company said the trial aims to assess safety, tolerability, and exploratory efficacy of both regimens in patients diagnosed with PSP, a rare neurodegenerative disease characterized by balance difficulties, eye movement disorders, and cognitive decline. AZP2006 is described as an orally administered small molecule designed to reduce neuroinflammation and protect neurons.
According to the company, the trial is organized under the CurePSP initiative and will use a shared control group to accelerate evaluation of multiple potential treatments. Alzprotect claims inclusion of AZP2006 reflects its therapeutic potential based on preclinical and early clinical findings.
The company said it expects the study to help determine whether AZP2006 can slow disease progression or improve symptoms in PSP patients. Alzprotect claims the trial marks an important milestone in advancing its strategy to target neurodegenerative tauopathies.
The company also noted AZP2006 previously received orphan drug designation in Europe and the United States for the treatment of PSP.
